drugset / Trial / NCT03003884
A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy
RandomizedParallel-groupSingle-blindOther
Summary
The purpose of this study is to find out the optimal dose for Remimazolam Tosilate as a procedural sedative during a diagnostic upper GI endoscopy and to assess its efficacy and safety profile comparing to propofol.
Timeline
- Start
- 2016-11
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Propofol | Small molecule | 1.5 mg/kg | Intravenous |
| Subject | Remimazolam | Small molecule | 5 mg | Intravenous |
| Subject | Remimazolam | Small molecule | 7 mg | Intravenous |
| Subject | Remimazolam | Small molecule | 8 mg | Intravenous |
Indications
No indication recorded.